Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T20:56:15.007Z Has data issue: false hasContentIssue false
  • English
  • Français

The usefulness of brain natriuretic peptide in simple congenital heart disease – a systematic review

Published online by Cambridge University Press:  20 September 2012

Jannet A. Eindhoven ,
Annemien E. van den Bosch ,
Eric Boersma  and
Jolien W. Roos-Hesselink
Jannet A. Eindhoven
Affiliation:
Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Annemien E. van den Bosch
Affiliation:
Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Eric Boersma
Affiliation:
Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Jolien W. Roos-Hesselink*
Affiliation:
Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
*
Correspondence to: Professor J. W. Roos-Hesselink, Department of Cardiology, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Tel: +31 10 7032432; Fax: +31 10 7035498; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Brain natriuretic peptide and N-terminal pro-brain natriuretic peptide are two well-established markers for cardiac failure in acquired heart disease. Nevertheless, the clinical utility of these markers in patients with congenital heart disease remains unclear. Therefore, the aim of this study was to evaluate the diagnostic and prognostic value of these markers in patients with congenital heart disease. A PubMed and EMBASE literature search was executed with focus on the most common simple congenital heart defects, atrial septal defect and ventricular septal defect. Data on brain natriuretic peptide measurement, cardiac function parameters, and follow-up were collected. In patients with atrial or ventricular septal defect, brain natriuretic peptide levels were mildly increased when compared with healthy age-matched controls. Shunt severity and pulmonary artery pressure correlated strongly with natriuretic peptide levels. A clear association between brain natriuretic peptide and functional class was demonstrated. After closure of the defect, a rise in brain natriuretic peptide levels in the first hours to days was observed. After longer follow-up, natriuretic peptide levels decreased and became comparable to pre-procedural values. In conclusion, this systematic review shows that brain natriuretic peptide levels are mildly increased in patients with unrepaired and repaired atrial or ventricular septal defect. Brain natriuretic peptide measurement might be a useful additional tool in the diagnostic work-up of patients with atrial or ventricular septal defect. Further investigation in a larger, prospective study with long-term follow-up is warranted to elucidate the true prognostic value of natriuretic peptides in patients with simple congenital heart disease.

Keywords

Congenital heart diseaseatrial septal defectventricular septal defectbrain natriuretic peptideN-terminal pro-brain natriuretic peptidecardiac function
Type
Review Article
Information
Cardiology in the Young , Volume 23 , Issue 3 , June 2013 , pp. 315 - 324
Copyright
Copyright © Cambridge University Press 2012 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. van der Linde, D, Konings, EE, Slager, MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 2241–2247.Google Scholar
2. Levin, ER, Gardner, DG, Samson, WK. Natriuretic peptides. N Engl J Med 1998; 339: 321–328.Google Scholar
3. Jessup, M, Abraham, WT, Casey, DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977–2016.Google Scholar
4. Uz, O, Aparci, M, Acar, G, et al. Association of plasma B-type natriuretic peptide levels with shunt size in young adults with atrial septal defect. Echocardiography 2011; 28: 243–247.Google Scholar
5. Jan, SL, Fu, YC, Hwang, B, Lin, SJ. B-type natriuretic peptide in children with atrial or ventricular septal defect: a cardiac catheterization study. Biomarkers 2012; 17: 166–171.Google Scholar
6. Masutani, S, Taketazu, M, Mihara, C, et al. Usefulness of early diastolic mitral annular velocity to predict plasma levels of brain natriuretic peptide and transient heart failure development after device closure of atrial septal defect. Am J Cardiol 2009; 104: 1732–1736.Google Scholar
7. Attenhofer Jost, CH, Oechslin, E, Seifert, B, et al. Remodelling after surgical repair of atrial septal defects within the oval fossa. Cardiol Young 2002; 12: 506–512.Google Scholar
8. Chamakou, AC, Dede, E, Moutafi, A, et al. Neurohormonal and cytokine fluctuations following transcatheter closure for an atrial septal defect. Cytokine 2012; 57: 130–135.Google Scholar
9. Eerola, A, Jokinen, E, Pihkala, JI. Serum levels of natriuretic peptides in children with various types of loading conditions. Scand Cardiovasc J 2009; 43: 187–193.Google Scholar
10. Eerola, A, Pihkala, JI, Boldt, T, Mattila, IP, Poutanen, T, Jokinen, E. Hemodynamic improvement is faster after percutaneous ASD closure than after surgery. Catheter Cardiovasc Interv 2007; 69: 432–441; discussion 442.Google Scholar
11. Kunii, Y, Kamada, M, Ohtsuki, S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003; 57: 191–197.Google Scholar
12. Mir, TS, Falkenberg, J, Friedrich, B, et al. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young 2005; 15: 396–401.Google Scholar
13. Muta, H, Ishii, M, Maeno, Y, Akagi, T, Kato, H. Quantitative evaluation of the changes in plasma concentrations of cardiac natriuretic peptide before and after transcatheter closure of atrial septal defect. Acta Paediatr 2002; 91: 649–652.Google Scholar
14. Nagaya, N, Nishikimi, T, Uematsu, M, et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998; 136: 297–301.Google Scholar
15. Nakagawa, K, Akagi, T, Taniguchi, M, et al. Transcatheter closure of atrial septal defect in a geriatric population. Catheter Cardiovasc Interv 2012; 80: 84–90.Google Scholar
16. Schoen, SP, Zimmermann, T, Kittner, T, et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur J Heart Fail 2007; 9: 660–666.Google Scholar
17. Takaya, J, Ikemoto, Y, Teraguchi, M, Nogi, S, Kobayashi, Y. Plasma nitric oxide products correlate with cardiac index of congenital heart disease. Pediatr Cardiol 2000; 21: 378–381.Google Scholar
18. Trojnarska, O, Szyszka, A, Gwizdala, A, et al. Evaluation of exercise capacity with cardiopulmonary exercise testing and type B natriuretic peptide concentrations in adult patients with patent atrial septal defect. Cardiology 2006; 106: 154–160.Google Scholar
19. Weber, M, Dill, T, Deetjen, A, et al. Left ventricular adaptation after atrial septal defect closure assessed by increased concentrations of N-terminal pro-brain natriuretic peptide and cardiac magnetic resonance imaging in adult patients. Heart 2006; 92: 671–675.Google Scholar
20. Wu, ET, Akagi, T, Taniguchi, M, et al. Differences in right and left ventricular remodeling after transcatheter closure of atrial septal defect among adults. Catheter Cardiovasc Interv 2007; 69: 866–871.Google Scholar
21. Chen, LP, Wei, TM, Wang, LX. Relationship between pericardial fluid B-type natriuretic peptide and ventricular structure and function. Arch Med Res 2007; 38: 326–329.CrossRefGoogle ScholarPubMed
22. Mainwaring, RD, Parise, C, Wright, SB, Juris, AL, Achtel, RA, Fallah, H. Brain natriuretic peptide levels before and after ventricular septal defect repair. Ann Thorac Surg 2007; 84: 2066–2069.Google Scholar
23. Man, BL, Cheung, YF. Plasma brain natriuretic peptide and systemic ventricular function in asymptomatic patients late after the Fontan procedure. Heart Vessels 2007; 22: 398–403.Google Scholar
24. Oyamada, J, Toyono, M, Shimada, S, et al. Noninvasive estimation of left ventricular end-diastolic pressure using tissue Doppler imaging combined with pulsed-wave Doppler echocardiography in patients with ventricular septal defects: a comparison with the plasma levels of the B-type natriuretic peptide. Echocardiography 2008; 25: 270–277.Google Scholar
25. Paul, MA, Backer, CL, Binns, HJ, et al. B-type natriuretic peptide and heart failure in patients with ventricular septal defect: a pilot study. Pediatr Cardiol 2009; 30: 1094–1097.Google Scholar
26. Suda, K, Matsumura, M, Matsumoto, M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45: 249–254.Google Scholar
27. Toyono, M, Harada, K, Tamura, M, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. Pediatr Cardiol 2008; 29: 65–69.Google Scholar
28. Westerlind, A, Wahlander, H, Lindstedt, G, Lundberg, PA, Holmgren, D. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004; 93: 340–345.Google Scholar
29. Trojnarska, O, Gwizdala, A, Katarzynski, S, et al. The BNP concentrations and exercise capacity assessment with cardiopulmonary stress test in cyanotic adult patients with congenital heart diseases. Int J Cardiol 2010; 139: 241–247.CrossRefGoogle ScholarPubMed
30. Iversen, K, Jensen, AS, Jensen, TV, Vejlstrup, NG, Sondergaard, L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010; 31: 1124–1131.Google Scholar
31. Williams, R, Houser, L, Miner, P, Aboulhosn, J. Efficacy and safety of bosentan in adults with simple and complex Eisenmenger's syndrome. Congenit Heart Dis 2012; 7: 12–15.Google Scholar
32. Redfield, MM, Rodeheffer, RJ, Jacobsen, SJ, Mahoney, DW, Bailey, KR, Burnett, JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976–982.Google Scholar